ACIP COVID-19 Vaccines Work Group

Dr. Beth Bell, Work Group Chair

December 1, 2020
Background

- ACIP responding to ongoing pandemic and accelerated vaccine development through scheduling of additional ACIP meetings

- At the November 23rd meeting, ACIP reviewed:
  - Evidence to Recommendation Framework:
    Public Health Problem, Resource Use and Equity Domains
  - Evidence to Recommendation Framework:
    Values, Acceptability and Feasibility Domains
  - Phased Allocation of COVID-19 Vaccines
COVID-19 Work Group activities – November 2020

- COVID-19 Vaccine Work Group meets weekly

- Topics covered since last ACIP meeting:
  - Additional discussions around Phase 1a populations
  - Clinical considerations for populations included in Phase 1a
Today’s agenda

- Allocation of initial supplies of COVID-19 vaccine: Phase 1a
  Dr. Kathleen Dooling (CDC)

- Clinical considerations for populations included in Phase 1a
  Dr. Sara Oliver (CDC)

- Post-authorization safety monitoring update
  Dr. Tom Shimabukuro (CDC)

- Public Comment

- **Vote:**
  Allocation of initial supplies of COVID-19 vaccine: Phase 1a
Vaccine Update

- **Two** COVID-19 vaccine manufacturers announced filing with U.S. FDA for Emergency Use Authorization
  - Pfizer/BioNTech announced submission on November 20, 2020¹
  - Moderna announced submission on November 30, 2020²

¹Pfizer and BioNTech to Submit Emergency Use Authorization Request Today to the U.S. FDA for COVID-19 Vaccine | Pfizer
²Moderna Announces Primary Efficacy Analysis in Phase 3 COVE Study for Its COVID-19 Vaccine Candidate and Filing Today with U.S. FDA for Emergency Use Authorization | Moderna, Inc. (modernatx.com)
**Work group members**

**ACIP members**
- Beth Bell (chair)
- Grace Lee
- Jose Romero
- Keipp Talbot

**Ex-officio/government members**
- FDA: Doran Fink, Rachel Zhang
- NIH: Chris Roberts
- IHS: Thomas Weiser, Jillian Doss-Walker
- DOD: Bryan Schumacher
- CMS: Jeff Kelman
- BARDA: Christine Oshansky
- HHS: David Kim

**CDC Co-leads**
- Kathleen Dooling
- Sara Oliver

**Liaisons**
- AAFP: Jonathan Temte
- AAP: Sean O’Leary
- ACOG: Denise Jamieson (primary), Laura Riley (alternate)
- ACP: Jason Goldman
- AGS: Ken Schmader
- AIM: Rob Shechter (primary), Jane Zucker (alternate)
- AMA: Sandra Fryhofer
- ANA: Kendra McMillan (primary), Ruth Francis (alternate)
- APhA: Michael Hogue
- ASTHO: Marcus Plescia
- CSTE: Susan Lett
- IDSA: Jeff Duchin (primary), Carol Baker (alternate)

**Liaisons, cont’d**
- NACCHO: Matt Zahn (primary), Jeff Duchin (alternate)
- NACI: Matthew Tunis (primary), Linlu Zhao (alternate)
- NFID: Bill Schaffner (primary), Marla Dalton (alternate)
- NMA: Oliver Brooks
- SHEA: Marci Drees

**Consultants**
- Ed Belongia (safety)
- Matthew Daley (safety)
- Kathy Kinlaw (ethics)
- Dayna Matthew (health equity)
- Kathleen Neuzil (vaccinology)
- Stanley Perlman (microbiology/immunology)
CDC participants

- Doug Campos-Outcalt
- Mary Chamberland
- Thomas Clark
- Amanda Cohn
- Jean Cox-Ganser
- Katie Curran
- Jonathan Duffy
- Anthony Fiore
- Mark Freedman
- Sue Gerber
- Jack Gersten
- Susan Goldstein
- Sam Graitcer
- Lisa Grohskopf
- Julia Gargano
- Rita Helfand
- Terri Hyde
- Tara Jatlaoui
- Cynthia Jorgensen
- Erin Kennedy
- Ram Koppaka
- Jessica MacNeil
- Mona Marin
- Sarah Mbaeyi
- Nancy McClung
- Lucy McNamara
- Rebecca Morgan
- Titilope Oduyebo
- Christina Ottis
- Anita Patel
- Janell Routh
- Stephanie Schrag
- Tom Shimabukuro
- Natalie Thornburg
- Jennifer Verani
- Megan Wallace
- Cindy Weinbaum
- Yon Yu
- Jane Zucker
Thank you!

The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.